Q1 2026 Belite Bio Inc Earnings Call Transcript
Key Points
- Belite Bio Inc (BLTE) has initiated the NDA rolling submission to the FDA for STARGUS disease and is on track to complete it by the second quarter of 2026.
- The company has completed enrollment in its Phase II/III DRAGON 2 clinical trial, which is a registration-enabling study for approval in Japan.
- Belite Bio Inc (BLTE) has a strong cash position with $799 million in cash equivalents and U.S. Treasury bills, providing ample capital to execute its goals.
- The company is actively building its commercial infrastructure and has hired all commercial leadership positions in preparation for the launch.
- Belite Bio Inc (BLTE) is engaging with the retinal community to raise awareness of SARA disease and is focused on preparing for a strong commercial launch.
- R&D expenses increased significantly to $15.7 million in Q1 2026 from $9.4 million in Q1 2025, driven by higher spending on clinical trials and manufacturing.
- SG&A expenses also rose to $17 million in Q1 2026 from $6.1 million in Q1 2025, primarily due to increased share-based compensation and team expansion.
- The GAAP net loss for the quarter was $26.9 million, compared to $14.3 million in the same period last year.
- There is uncertainty regarding the FDA's requirement for DRAGON 2 study results for U.S. approval, which could impact timelines.
- The company is still in the process of determining the pricing strategy for its drug, with potential pricing bands ranging from $350,000 to $500,000, but no final decision has been made.
Ladies and gentlemen, thank you for joining us and welcome to the BLI Bio First Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press *9 to raise your hand and *6 to unmute. I will now hand the conference over to Julie Fallon. Please go ahead.
Good afternoon, everyone.
Thank you for joining us.
On the call today are Dr. Tom Lin, Chairman and CEO of BeLive Bio, Dr. Hendrick Scholl, Chief Medical Officer, Dr. Nathan Mata, Chief Scientific Officer, and Haoyoung Zhang, Chief Financial Officer.
Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs.
These statements are subject to certain risks and uncertainties, and actual results may differ materially.
We encourage you to consult the risk factors discussed in our SEC filings
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
